IN THE UNITED STATE PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Michael K. Skinner et al.)	
)	Group Art Unit: Unassigned
Application No.: Unassigned)	
)	Examiner: Unassigned
Filed: Herewith)	•
	•	

For: A METHOD OF DETERMINING TUMOR CHARACTERISTICS BY DETERMINING ABNORMAL COPY NUMBER OR EXPRESSION LEVEL OF LIPID-ASSOCIATED GENES

STATEMENT TO SUPPORT FILING SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821-1.825

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In order to comply with 37 CFR §§ 1.821-1.825, Applicants refer to the Sequence Listing and the computer readable form thereof filed in the U.S. Patent Application Serial No. 09/676,052, filed September 28, 2000. That application contains sequence information identical to that of the present application. No new matter is added by this submission.

Applicants hereby request that the Sequence Listing of the parent application be used to fulfill the sequence disclosure requirements for this application pursuant to 37 CFR § 1.821e.

Applicants enclose a paper copy of the sequence listing which upon information and belief is identical to the computer readable copy filed in the application.

Respectfully submitted,

BAKER & HOSTETLER LLP

Koepetz

Sunit Talapatra, Ph.D.

Patent Agent

Registration No. 54,482

Date: August 26, 2003

Baker & Hostetler LLP

Washington Square, Suite 1100

1050 Connecticut Avenue, N.W.

Washington, D.C. 20036

Telephone: (202) 861 1500

Facsimile: (202) 861 1783